Interpreting Efficacy and the Value of a Coordinated Program

This segment digs into the key efficacy findings from the real-world analyses and how they measure against the pivotal trial that supported approval. The faculty note that response rates among patients who reach infusion appear comparable to trial results, while acknowledging these were investigator-assessed rather than held to stringent centralized criteria. A central theme is durability: while not every response proves lasting, a meaningful subset of patients, particularly those achieving complete responses, experience long-term benefit. The experts stress that questions remain about longer-term outcomes given the limited follow-up of observational data. Equally important is the operational side of care. The discussion highlights how building a coordinated program, supported by dedicated navigators who manage the complex logistics of surgery, manufacturing, insurance, and scheduling, can dramatically shorten timelines and get more patients to treatment. The faculty frame program organization as being just as consequential as the efficacy data itself.